Science Without Borders, Advancing Toward Cure: EHA 2026 Opens in Stockholm, Charting a New Era of Global Collaboration and High-Quality Development in Hematology

Science Without Borders, Advancing Toward Cure: EHA 2026 Opens in Stockholm, Charting a New Era of Global Collaboration and High-Quality Development in Hematology

In June 2026, the European Hematology Association (EHA) Congress officially opened in Stockholm, Sweden, bringing together the global hematology community for one of the field’s most influential scientific events. As the largest and most prestigious annual meeting in hematology, EHA 2026 not only showcased groundbreaking scientific discoveries but also unveiled strategic initiatives that will help shape the future of hematology research and patient care over the next decade.
EHA 2026 Echoes | Hui Wang and Man Chen: Impact of Two Antithymocyte Globulin Conditioning Regimens on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation

EHA 2026 Echoes | Hui Wang and Man Chen: Impact of Two Antithymocyte Globulin Conditioning Regimens on Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation

The 2026 Congress of the European Hematology Association (EHA 2026), held from June 11–14 in Stockholm, Sweden, brought together leading experts from around the world to showcase the latest advances in hematology research, translational medicine, and clinical practice.
EHA 2026 Echoes | Ruijuan Sun and Hai He: Allogeneic HSCT Overcomes the Poor Prognosis Associated with NUP98::NSD1-Positive Acute Myeloid Leukemia

EHA 2026 Echoes | Ruijuan Sun and Hai He: Allogeneic HSCT Overcomes the Poor Prognosis Associated with NUP98::NSD1-Positive Acute Myeloid Leukemia

The 2026 Congress of the European Hematology Association (EHA 2026) was held from June 11 to 14 in Stockholm, Sweden. As one of the most influential international meetings in hematology, EHA brings together leading experts from around the world to showcase the latest advances in basic science, translational research, and clinical practice.
ASCO Voices from China | Lijuan Chen: A Novel Highly Selective HDAC Inhibitor–Based Triplet Regimen Offers a New Strategy for Relapsed/Refractory Multiple Myeloma

ASCO Voices from China | Lijuan Chen: A Novel Highly Selective HDAC Inhibitor–Based Triplet Regimen Offers a New Strategy for Relapsed/Refractory Multiple Myeloma

The rapid emergence of CAR-T cell therapies and bispecific antibodies has transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM), leading to substantial improvements in patient outcomes. However, limitations related to accessibility, treatment costs, manufacturing complexity, and toxicity management continue to restrict their widespread use. As a result, there remains a pressing need for innovative therapies that combine efficacy, safety, and broad clinical applicability.
ASCO Voices from China | Huafeng Wang: Advancing Innovation and Expanding Possibilities—A Novel BCL-2 Inhibitor Brings New Hope for AML and MDS

ASCO Voices from China | Huafeng Wang: Advancing Innovation and Expanding Possibilities—A Novel BCL-2 Inhibitor Brings New Hope for AML and MDS

Despite significant advances in recent years, the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) continues to present major clinical challenges. Existing therapies offer limited efficacy for many patients, particularly those with high-risk disease, highlighting a substantial unmet medical need.